/ Cadila Healthcare Receives Approval From USFD ~ Ways2Capital|Stock Tips|Stock Market Tips|Intraday Stock Tips|Stock Trading Tips|NSE BSE Tips

Monday, 10 July 2017

USFDA gives final approval to Cadila Healthcare to market Doxazosin tables USP 1mg, 2mg, 4mg and 8mg which is a selective alpha blocker used to treat high blood pressure and urinary retentions associated with benign prostatic hyperplasia. While USFDA gives the tentative approval to the company for Lurasidone Hydrochloride tablets 20mg, 40mg, 60mg and 120mg, this drug is an atypical anti-psychotic used in the treatment of schizophrenia.

Lurasidone Hydrochloride and Doxazosin tables both will be produced the company’s formulation, manufacturing facility at the Pharma SEZ in Ahmadabad.

The company has 59117 NSE+BSE shares traded in the counter and had a Rs 52855.83cr current market cap.

For Quick Trial – 8962000225 ✔
or mail us here: info@ways2capital.com
✆ - 0731-6626222 | Toll Free - 1800-3010-2007 
Give a Missed Call for Free Trial - 09699997717